{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-016839","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.397761+00:00","generated_at":"2026-06-03T06:06:37.704050+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Oncotelic sells necroptosis cancer therapy assets to Mosaic for up to $30M","bullets":["Mosaic to issue $15M in shares at closing; Oncotelic may earn $15M more in cash/shares based on milestones.","Transaction includes Oncotelic's CA4P clinical-stage necroptosis therapies and AI tech for immunotherapy combos.","Mosaic to fund $2.0-$2.5M annual development budget; Oncotelic to loan short-term operational costs until June 1, 2024.","If Oncotelic cannot help raise $2M for Mosaic, transaction may become reverse merger.","Parties to negotiate definitive agreement; closing subject to customary due diligence."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-016839","json":"https://secwatch.observer/filing/0001493152-24-016839.json","markdown":"https://secwatch.observer/filing/0001493152-24-016839.md","text":"https://secwatch.observer/filing/0001493152-24-016839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315224016839/0001493152-24-016839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315224016839/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:06:37.704050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}